Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, J.
Right arrow Articles by Rostami-Hodjegan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, J.
Right arrow Articles by Rostami-Hodjegan, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on November 1, 2006
Journal of Psychopharmacology, Vol. 20, No. 6, 842-849 (2006)
DOI: 10.1177/0269881106065907

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA

Jiansong Yang

Masoud Jamei

Amir Heydari

Karen R. Yeo

Simcyp Limited, Sheffield, UK

Rafael de la Torre

Magí Farré

Institut Municipal d'Investigació Mèdica, Barcelona, Spain

Geoffrey T. Tucker

Amin Rostami-Hodjegan

University of Sheffield, Sheffield, UK

The aim of this study was to model the in vivo kinetic consequences of mechanism-based inhibition (MBI) of CYP2D6 by 3,4 methylenedioxymethamphetamine (MDMA, ecstasy). A model with physiologically-based components of drug metabolism was developed, taking account of change in the hepatic content of active CYP2D6 due to MBI by MDMA. Based on the in vitro information, plasma concentration time profiles of MDMA after various doses were computed and compared with reported observations. The analysis suggested that a typical recreational MDMA dose could inactivate most hepatic CYP2D6 within an hour, and the return to a basal level of CYP2D6 could take at least 10 days. Thus, the genetic polymorphism of CYP2D6 and coadministration of CYP2D6 inhibitors may have less impact on MDMA pharmacokinetics and the risk of acute toxicity than previously thought. This is consistent with clinical observations that indicate no obvious link between inherited CYP2D6 deficiency and acute MDMA intoxication.

Key Words: ecstasy • inactivation • MDMA • mechanism-based inhibition • modelling

References

  • Back T, Fogel D B, Michalewics Z(1997) Handbook of Evolutionary Computation. Institute of Physics Pub., Oxford University Press, Bristol .
  • Bertelsen K M, Venkatakrishnan K, von Moltke L L, Obach R S, Greenblatt D J (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine . Drug Metab Dispos 31: 289–293 .[Abstract/Free Full Text]
  • de la Torre R, Farre M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans . Trends Pharmacol Sci 25: 505–508 .[CrossRef][Medline] [Order article via Infotrieve]
  • de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset P N, Segura J, Cami J (2000) Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans . Br J Clin Pharmacol 49: 104–109 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Delaforge M, Jaouen M, Bouille G (1999) Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450 . Particular involvement of CYP 2D. Environ Toxicol and Pharmacol 7: 153–158 .
  • Deray G, Bochet M, Katlama C, Bricaire F (1998) Nephrotoxicity of ritonavir . Presse Medicale 27: 1801–1803 .
  • Farre M, de la Torre R, Oathuna M B, Roset PN, Peiro A M, Torrens M, Ortuno J, Pujadas M, Cami J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics . Psychopharmacology (Berl) 173: 364–375 .[CrossRef][Medline] [Order article via Infotrieve]
  • Gilhooly T C, Daly A K (2002) CYP2D6 deficiency, a factor in ecstasy related deaths? Br J Clin Pharmacol 54: 69–70 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Goldberg D E (1989) Genetic Algorithms in Search, Optimisation, and Machine Learning. Addison Wesley, Wokingham .
  • Green A R, Mechan A O, Elliott J M, O'Shea E, Colado M I (2003) The pharmacology and clinical pharmacology of 3,4-methylene dioxymethamphetamine (MDMA, ‘ecstasy’) . Pharmacol Rev 55: 463–508 .[Abstract/Free Full Text]
  • Henry J A, Hill I R (1998) Fatal interaction between ritonavir and MDMA . Lancet 352: 1751–1752 .[ISI][Medline] [Order article via Infotrieve]
  • Henry J A, Jeffreys K J, Dawling S (1992) Toxicity and deaths from 3,4 methylenedioxymethamphetamine (Ecstasy) . Lancet 340: 384–387 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Hesse L M, von Moltke L L, Shader R I, Greenblatt D J (2001) Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion . Drug Metab Dispos 29: 100–102 .[Abstract/Free Full Text]
  • Heydari A, Yeo K R, Lennard M S, Ellis S W, Tucker G T, Rostami-Hodjegan A (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine . Drug Metab Dispos 32: 1213–1217 .[Abstract/Free Full Text]
  • Holland J H (1975) Adaptation in Natural and Artificial Systems. University of Michigan Press, Ann Arbor, MI .
  • Ingelman-Sundberg M, Oscarson M, McLellan R A (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment . Trends Pharmacol Sci 20: 342–349 .[CrossRef][Medline] [Order article via Infotrieve]
  • Jones D C, Duvauchelle C, Ikegami A, Olsen C M, Lau S S, de la Torre R, Monks T J (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain . J Pharmacol Exp Ther 313: 422–431 .[Abstract/Free Full Text]
  • Kreth K P, Kovar K A, Schwab M, Zanger U M (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of ‘Ecstasy’-related designer drugs . Biochem Pharmacol 59: 1563–1571 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Lappin G, Garner R C (2003) Big physics, small doses: the use of AMS and PET in human microdosing of development drugs . Nature Rev Drug Discov 2: 233–240 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • O'Donohoe A, O'Flynn K, Shields K, Hawi Z, Gill M (1998) MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6 . Addiction Biol 3: 309–314 .
  • Ramamoorthy Y, Yu A M, Suh N, Haining R L, Tyndale R F, Sellers E M (2002) Reduced(+/-)-3,4-methylenedioxymethamphetamine (‘Ecstasy’) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro . Biochem Pharmacol 63: 2111–2119 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Renwick A B, Watts P S, Edwards R J, Barton P T, Guyonnet I, Price R J, Tredger J M, Pelkonen O, Boobis A R, Lake B G (2000) Differential maintenance of Cytochrome P450 enzymes in cultured precision-cut human liver slices . Drug Metab Dispos 28: 1202–1209 .[Abstract/Free Full Text]
  • Schwab M, Seyringer E, Brauer R B, Hellinger A, Griese E U (1999) Fatal MDMA intoxication . Lancet 353: 593–594 .[ISI][Medline] [Order article via Infotrieve]
  • Segura M, Farre M, Pichini S, Peiro A M, Roset P N, Ramirez A, Ortuno J, Pacific R, Zuccaro P, Segura J, de la Torre R (2005) Contribution of Cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe . Clin Pharmacokinet 44: 649–660 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Silverman R B (1988) Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology. CRC Press, Boca Raton, FL .
  • Tucker G T, Lennard M S, Ellis S W, Woods H F, Cho A K, Lin L Y, Hiratsuka A, Schmitz D A, Chu T Y Y (1994) The demethylenation of methylenedioxymethamphetamine (ecstasy) by debrisoquine hydroxylase (CYP2D6) . Biochem Pharmacol 47: 1151–1156 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Valentin J (2002) Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. Pergamon, Oxford .
  • von Moltke L L, Durol A L B, Duan S X, Greenblatt D J (2000) Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole . Eur J Clin Pharmacol 56: 259–261 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • von Moltke L L, Greenblatt D J, Grassi J M, Granda B W, Duan S X, Fogelman S M, Daily J P, Harmatz J S, Shader R I (1998) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir . J Clin Pharmacol 38: 106–111 .[Abstract]
  • Wilson Z E, Rostami-Hodjegan A, Burn J L, Tooley A, Boyle J, Ellis S W, Tucker G T (2003) Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver . Br J Clin Pharmacol 56: 433–440 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Wu D F, Otton S V, Inaba T, Kalow W, Sellers E M (1997) Interactions of amphetamine analogs with human liver CYP2D6 . Biochem Pharmacol 53: 1605–1612 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Yang J, Rostami-Hodjegan A (2004) Metabolic kinetic constants when drugs cause mechanism-based inhibition of their own metabolism . Drug Metab Rev 36 (suppl. 1): 292-292 .
  • Yang J, Jamei M, Yeo K R, Rostami-Hodjegan A, Tucker G T (2005) Kinetic values for mechanism-based inhibition: assessment of bias introduced by the conventional experimental protocol . Eur J of Pharm Sci 26: 334–340 .
  • Yeo K R, Rostami-Hodjegan A, Tucker G T (2004) Abundance of cytochrome P450 in human liver: a meta-analysis . Br J Clin Pharmacol 57: 687–688

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, J.
Right arrow Articles by Rostami-Hodjegan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, J.
Right arrow Articles by Rostami-Hodjegan, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?